Inhibiting peripheral serotonin activates liver AMPK and reduces monocyte-derived macrophages and fibrosis

Battsetseg Batchuluun1, Tinne Thoné2, Andre Djalalvandi1

  • 1Centre for Metabolism, Obesity and Diabetes Research, McMaster University, Hamilton, ON, Canada; Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, Hamilton, ON, Canada.

Cell Reports
|November 27, 2025
PubMed

Insights

Inhibition of peripheral serotonin (5-hydroxytryptamine) prevents metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis by reducing monocyte recruitment. This highlights serotonin and AMPK

Area of Science:

  • Hepatology
  • Immunology
  • Metabolic Diseases

Background:

  • Monocyte-derived liver macrophages drive metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis.
  • Mechanisms of monocyte recruitment in MASH remain poorly understood.

Purpose of the Study:

  • To investigate the role of peripheral serotonin (5-hydroxytryptamine) in monocyte recruitment and MASH pathogenesis.
  • To explore the link between serotonin, AMP-activated protein kinase (AMPK), and liver fibrosis.

Main Methods:

  • Utilized Tph1 knockout mice fed a high-fat, high-fructose diet at thermoneutrality.
  • Employed liver flow cytometry and single-nucleus sequencing to analyze immune cell populations.
  • Assessed the impact of serotonin (5HT) injection on monocyte levels.

Main Results:

  • Genetic deletion of Tph1, inhibiting peripheral serotonin, prevented MASH development independently of body weight changes.
  • Tph1 knockout mice exhibited reduced pro-inflammatory Ly6Chigh monocytes, Kupffer cells, and lipid-associated macrophages.
  • Serotonin inhibition increased liver AMPK activity, leading to decreased CCL2 and reduced monocyte recruitment.

Conclusions:

  • Peripheral serotonin signaling is a critical driver of monocyte recruitment in MASH.
  • Targeting peripheral serotonin offers a potential therapeutic strategy for MASH and liver fibrosis.
  • Serotonin and AMPK represent interconnected energy sensors involved in obesity-associated liver disease.